कृपया अन्य खोज का प्रयास करें
Entera Bio Ltd., a clinical-stage company, focuses on the development and commercialization of orally delivered peptide and protein therapeutics for unmet medical needs. The company’s product candidates include the EB612, which is in Phase II clinical trials for the treatment of hypoparathyroidism; and EB613 that has completed Phase II clinical trials for the treatment of osteoporosis, as well as is in Phase I clinical trials for the treatment of stress fractures. Its other product candidate is GLP-2, which is in preclinical trial for the treatment of short bowl syndrome; and OXM for the treatment of obesity and metabolic diseases. The company has a research collaboration and license agreement with the Amgen Inc. for the development and discovery of clinical candidates in the field of inflammatory disease and other serious illnesses. Entera Bio Ltd. was incorporated in 2009 and is based in Jerusalem, Israel.
नाम | आयु | पहले | शीर्षक |
---|---|---|---|
Gerald M. Lieberman | 75 | 2014 | Independent Chairman of the Board |
Yonatan Malca | 56 | 2011 | Independent Director |
Gerald M. Ostrov | 73 | 2019 | Independent Director |
Ron Mayron | 59 | 2021 | Independent Director |
Sean Ellis | 47 | 2019 | Independent Director |
Miranda J. Toledano | 45 | 2018 | CEO & Director |
Roger J. Garceau | 69 | 2016 | Director |
Haya Taitel | - | 2023 | Independent Director |
Steven R. Goldstein | 72 | 2023 | Member of Clinical & Scientific Advisory Board |
क्या आप सच में %USER_NAME% को ब्लॉक करना चाहते हैं?
ऐसा करके, आप और %USER_NAME% नहीं देख पाएंगे किसी अन्य के Investing.com की पोस्ट में से कोई भी।
%USER_NAME% को सफलतापूर्वक आपकी ब्लॉक सूची में जोड़ लिया गया है
क्योंकि आपने इस व्यक्ति को अनब्लॉक कर दिया है, आपको ब्लॉक को रिन्यू करने से पहले 48 घंटे प्रतीक्षा करनी होगी।
मुझे लगता है कि यह टिपण्णी:
धन्यवाद!
आपकी रिपोर्ट समीक्षा के लिए हमारे मॉडरेटर को भेजी गई है